Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice

Molecular Therapy

Volumn 23, Issue 1, 2015, Pages 53-62

  Ayers, Jacob I ^a   Fromholt, Susan ^a   Sinyavskaya, Olga ^a   Siemienski, Zoe ^a   Rosario, Awilda M ^a   Li, Andrew ^a   Crosby, Keith W ^a   Cruz, Pedro E ^a   Dinunno, Nadia M ^a   Janus, Christopher ^a   Ceballos Diaz, Carolina ^a   Borchelt, David R ^a   Golde, Todd E ^a   Chakrabarty, Paramita ^a   Levites, Yona ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 10; RAAV2/1; RAAV2/5; RAAV2/8; RAAV2/9; RECOMBINANT ADENO ASSOCIATED VIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; IL10 PROTEIN, MOUSE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

ADENO ASSOCIATED VIRUS; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CISTERNA MAGNA; CONTROLLED STUDY; DORSAL ROOT; GENE EXPRESSION; GENE TARGETING; HINDLIMB; LUMBAR SPINAL CORD; MOTOR NEURON DISEASE; MOUSE; NERVE FIBER; NEWBORN; NONHUMAN; SENSORY NERVE CELL; SEROTYPE; SIGNAL TRANSDUCTION; SPINAL CORD; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS ENTRY; ANIMAL; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEK293 CELL LINE; HUMAN; INTRASPINAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; PROCEDURES; REPORTER GENE; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ADENO-ASSOCIATED VIRUS; MIRIDAE; MURINAE; MUS; MUS MUSCULUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, NEWBORN; BRAIN; CAPSID; CISTERNA MAGNA; DEPENDOVIRUS; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; INJECTIONS, SPINAL; INTERLEUKIN-10; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; SPINAL CORD; SUPEROXIDE DISMUTASE; TRANSDUCTION, GENETIC;

EID: 84920561391     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.180     Document Type: Article

References (43)

1. Golde, TE, Borchelt, DR, Giasson, BI and Lewis, J (2013). Thinking laterally about neurodegenerative proteinopathies. J Clin Invest 123: 1847-1855.
2. Cederfjäll, E, Nilsson, N, Sahin, G, Chu, Y, Nikitidou, E, Björklund, T et al. (2013). Continuous DOPA synthesis from a single AAV: dosing and effcacy in models of Parkinson's disease. Sci Rep 3: 2157.
3. Murphy, SR, Chang, CC, Dogbevia, G, Bryleva, EY, Bowen, Z, Hasan, MT et al. (2013). Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease. Mol Ther 21: 1497-1506.
4. Furman, JL, Sama, DM, Gant, JC, Beckett, TL, Murphy, M P, Bachstetter, AD et al. (2012). Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32: 16129-16140.
5. Bu, J, Ashe, KM, Bringas, J, Marshall, J, Dodge, JC, Cabrera-Salazar, MA et al. (2012). Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 20: 1893-1901.
6. Cearley, CN, Vandenberghe, LH, Parente, MK, Carnish, ER, Wilson, JM and Wolfe, JH (2008). Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther 16: 1710-1718.
7. Chakrabarty, P, Ceballos-Diaz, C, Beccard, A, Janus, C, Dickson, D, Golde, TE et al. (2010). IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol 184: 5333-5343.
8. Levites, Y, Jansen, K, Smithson, LA, Dakin, R, Holloway, VM, Das, P et al. (2006). Intracranial adeno-associated virus-mediated delivery of anti-pan amyloid beta, amyloid beta40, and amyloid beta42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. J Neurosci 26: 11923-11928.
9. Mandel, RJ, Manfredsson, F P, Foust, KD, Rising, A, Reimsnider, S, Nash, K et al. (2006). Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13: 463-483.
10. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
11. Asokan, A, Schaffer, DV and Samulski, RJ (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 20: 699-708.
12. Chakrabarty, P, Rosario, A, Cruz, P, Siemienski, Z, Ceballos-Diaz, C, Crosby, K et al. (2013). Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain. PLoS One 8: e67680.
13. Foust, KD, Nurre, E, Montgomery, CL, Hernandez, A, Chan, CM and Kaspar, BK (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65.
14. Benkhelifa-Ziyyat, S, Besse, A, Roda, M, Duque, S, Astord, S, Carcenac, R et al. (2013). Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 21: 282-290.
15. Klaw, MC, Xu, C and Tom, VJ (2013). Intraspinal AAV injections immediately rostral to a thoracic spinal cord injury site effciently transduces neurons in spinal cord and brain. Mol Ther Nucleic Acids 2: e108.
16. Kaspar, BK, Lladó, J, Sherkat, N, Rothstein, JD and Gage, FH (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301: 839-842.
17. Henkel, JS, Beers, DR, Zhao, W and Appel, SH (2009). Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 4: 389-398.
18. Dayton, RD, Wang, DB and Klein, RL (2012). The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 12: 757-766.
19. Foust, KD, Wang, X, McGovern, VL, Braun, L, Bevan, AK, Haidet, AM et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
20. Hollis, ER 2nd, Kadoya, K, Hirsch, M, Samulski, RJ and Tuszynski, MH (2008). Effcient retrograde neuronal transduction utilizing self-complementary AAV1. Mol Ther 16: 296-301.
21. Bucher, T, Colle, MA, Wakeling, E, Dubreil, L, Fyfe, J, Briot-Nivard, D et al. (2013). scAAV9 intracisternal delivery results in effcient gene transfer to the central nervous system of a feline model of motor neuron disease. Hum Gene Ther 24: 670-682.
22. Zheng, C, Voutetakis, A, Metzger, M, Afone, S, Cotrim, AP, Eckhaus, MA et al. (2010). Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glands. Oral Dis 16: 269-277.
23. Towne, C, Setola, V, Schneider, BL and Aebischer, P (2011). Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic beneft in fALS mice. Mol Ther 19: 274-283.
24. Passini, MA, Bu, J, Richards, AM, Treleaven, CM, Sullivan, JA, O'Riordan, CR et al. (2014). Translational fdelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 25: 619-630.
25. Foust, KD, Salazar, DL, Likhite, S, Ferraiuolo, L, Ditsworth, D, Ilieva, H et al. (2013). Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther 21: 2148-2159.
26. Samaranch, L, San Sebastian, W, Kells, AP, Salegio, EA, Heller, G, Bringas, JR et al. (2014). AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinfammation driven by antigen-presenting cell transduction. Mol Ther 22: 329-337.
27. Gray, SJ, Nagabhushan Kalburgi, S, McCown, TJ and Jude Samulski, R (2013). Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 20: 450-459.
28. Snyder, BR, Gray, SJ, Quach, ET, Huang, JW, Leung, CH, Samulski, RJ et al. (2011). Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther 22: 1129-1135.
29. Chakrabarty, P, Ceballos-Diaz, C, Lin, WL, Beccard, A, Jansen-West, K, McFarland, NR et al. (2011). Interferon-γ induces progressive nigrostriatal degeneration and basal ganglia calcifcation. Nat Neurosci 14: 694-696.
30. Chakrabarty, P, Jansen-West, K, Beccard, A, Ceballos-Diaz, C, Levites, Y, Verbeeck, C et al. (2010). Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against infammation as a driving force for amyloid deposition. FASEB J 24: 548-559.
31. Chakrabarty, P, Tianbai, L, Herring, A, Ceballos-Diaz, C, Das, P and Golde, TE (2012). Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 7: 36.
32. Chakrabarty, P, Herring, A, Ceballos-Diaz, C, Das, P and Golde, TE (2011). Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo. Mol Neurodegener 6: 16.
33. Chiu, BC, Martin, BE, Stolberg, VR and Chensue, SW (2013). The host environment is responsible for aging-related functional NK cell defciency. J Immunol 191: 4688-4698.
34. Beers, DR, Henkel, JS, Zhao, W, Wang, J, Huang, A, Wen, S et al. (2011). Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134(Pt 5): 1293-1314.
35. Butovsky, O, Siddiqui, S, Gabriely, G, Lanser, AJ, Dake, B, Murugaiyan, G et al. (2012). Modulating infammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J Clin Invest 122: 3063-3087.
36. Zhao, W, Beers, DR, Liao, B, Henkel, JS and Appel, SH (2012). Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms. Neurobiol Dis 48: 418-428.
37. Boillée, S, Yamanaka, K, Lobsiger, CS, Copeland, NG, Jenkins, NA, Kassiotis, G et al. (2006). Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312: 1389-1392.
38. Beers, DR, Henkel, JS, Xiao, Q, Zhao, W, Wang, J, Yen, AA et al. (2006). Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103: 16021-16026.
39. Moore, KW, de Waal Malefyt, R, Coffman, RL and O'Garra, A (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765.
40. Yazawa, I, Giasson, BI, Sasaki, R, Zhang, B, Joyce, S, Uryu, K et al. (2005). Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45: 847-859.
41. Custer, SK, Garden, GA, Gill, N, Rueb, U, Libby, RT, Schultz, C et al. (2006). Bergmann glia expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by impairing glutamate transport. Nat Neurosci 9: 1302-1311.
42. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purifcation of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167.
43. Geiss, GK, Bumgarner, RE, Birditt, B, Dahl, T, Dowidar, N, Dunaway, DL et al. (2008). Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26: 317-325.